Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + toripalimab + chemotherapy as second-line treatment for unresectable or metastatic biliary tract carcinoma
ChiCTR2500099005Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib and toripalimab in biliary cancer, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: progression-free survival. Started Mar 2025; status: recruiting.
02
Drugs
surufatinibtoripalimab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2500099005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099005.